List of Excipients in Branded Drug LEADER OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION

Generic Drugs Containing LEADER OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION

Company	Ingredient	NDC	Excipient
CARDINAL HEALTH	olopatadine hydrochloride ophthalmic solution	70000-0717	BENZALKONIUM CHLORIDE
CARDINAL HEALTH	olopatadine hydrochloride ophthalmic solution	70000-0717	HYDROCHLORIC ACID
CARDINAL HEALTH	olopatadine hydrochloride ophthalmic solution	70000-0717	SODIUM CHLORIDE
CARDINAL HEALTH	olopatadine hydrochloride ophthalmic solution	70000-0717	SODIUM HYDROXIDE
CARDINAL HEALTH	olopatadine hydrochloride ophthalmic solution	70000-0717	SODIUM PHOSPHATE, MONOBASIC
CARDINAL HEALTH	olopatadine hydrochloride ophthalmic solution	70000-0717	WATER

What are the Most Frequently-Used Excipients in LEADER OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION?

# Of NDCs	Excipient
1	BENZALKONIUM CHLORIDE
1	HYDROCHLORIC ACID
1	SODIUM CHLORIDE
1	SODIUM HYDROXIDE
1	SODIUM PHOSPHATE, MONOBASIC
1	WATER

Leader Olopatadine Hydrochloride Ophthalmic Solution: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 7, 2026

Leader Olopatadine Hydrochloride Ophthalmic Solution is a generic ophthalmic allergy product based on olopatadine hydrochloride 0.1%. Its commercial position depends less on active-ingredient exclusivity and more on preservative selection, ocular-surface tolerability, packaging, retail distribution, and manufacturing cost. The current formulation uses a conventional preserved aqueous solution with benzalkonium chloride, phosphate buffer, sodium chloride, and edetate disodium. The strongest opportunities are preservative-free presentations, improved multidose delivery, private-label expansion, and differentiated ocular-surface formulations.

What is Leader Olopatadine Hydrochloride Ophthalmic Solution?

Leader Olopatadine Hydrochloride Ophthalmic Solution is a generic ophthalmic solution for allergic conjunctivitis. The product contains olopatadine hydrochloride equivalent to olopatadine 0.1%, or 1 mg/mL, and is marketed through the Leader private-label retail channel.

Product attribute	Current position
Active ingredient	Olopatadine hydrochloride
Strength	0.1%, equivalent to 1 mg/mL olopatadine
Dosage form	Sterile ophthalmic solution
Therapeutic use	Temporary relief of itching and redness associated with allergic conjunctivitis
Preservative	Benzalkonium chloride
Product type	Generic small-molecule ophthalmic product
Regulatory pathway	Generally ANDA-based for an equivalent olopatadine ophthalmic solution
Main commercial channel	Private-label pharmacy and retail distribution
Biosimilar exposure	None; olopatadine is a small molecule

Olopatadine is a selective histamine H1 antagonist and mast-cell stabilizer. The 0.1% formulation has traditionally been used as a twice-daily product. Higher-strength olopatadine products, including 0.2% and 0.7% formulations, have supported once-daily positioning in the U.S. market.

What excipients are used in Leader Olopatadine ophthalmic solution?

The formulation is a conventional buffered, isotonic, preserved aqueous ophthalmic solution. Public product labeling identifies the following inactive ingredients:

Excipient	Primary formulation function	Commercial and technical relevance
Benzalkonium chloride	Antimicrobial preservative	Low cost and established regulatory history; potential ocular-surface tolerability concern with repeated use
Dibasic sodium phosphate	Buffer component	Helps maintain pH during storage and use
Sodium chloride	Tonicity agent	Supports ocular comfort and isotonicity
Edetate disodium	Chelating agent	Binds metal ions and can improve preservative performance and chemical stability
Hydrochloric acid and sodium hydroxide	pH adjustment	Controls final formulation pH
Purified water	Vehicle	Forms the aqueous solution base

The formulation strategy is optimized for manufacturing simplicity, low cost, and compatibility with a multidose bottle. It does not materially differentiate the product from other generic olopatadine 0.1% solutions.

Why benzalkonium chloride matters

Benzalkonium chloride, commonly called BAK, is widely used in ophthalmic products because it is effective at low concentrations and is compatible with many multidose packaging systems. Its disadvantages are commercial rather than merely technical. Chronic exposure may be associated with ocular-surface irritation, tear-film disruption, and reduced tolerability in patients with dry eye or frequent dosing requirements.

For short-term seasonal use, BAK remains commercially acceptable. For chronic or recurrent allergy treatment, preservative-free or reduced-preservative products have greater differentiation potential.

Why edetate disodium is commercially useful

Edetate disodium is not a headline consumer ingredient, but it can support formulation robustness. It binds trace metal ions that can catalyze degradation or interfere with preservative performance. In a preserved ophthalmic product, the combination of BAK and a chelating agent can provide a practical microbiological-control system without requiring a more complex delivery platform.

What formulation patents protect olopatadine ophthalmic solutions?

The original olopatadine compound and branded ophthalmic products were protected by historical patents and regulatory exclusivity. Those barriers have largely expired for the 0.1% generic solution market.

Patent or exclusivity category	Current commercial relevance
Original olopatadine active-ingredient patents	Historical protection; no longer a practical barrier to generic 0.1% solution entry
Patanol 0.1% formulation protection	Historical protection; generic competition is established
Pataday 0.2% product protection	Historical protection; commercial relevance depends on the specific formulation and jurisdiction
Pazeo 0.7% product protection	Potentially relevant to higher-strength or once-daily competition, but not generally blocking for a 0.1% generic
Method-of-use patents	May have applied to specific dosing or indications; limited significance for standard allergic-conjunctivitis labeling after expiration
Device or packaging patents	Could affect proprietary preservative-free or multidose systems
Current formulation patents	No widely recognized blocking patent position for the standard preserved 0.1% solution

The FDA Orange Book should be used for the current patent listing and exclusivity record of each reference product. Patent risk is product-specific because the 0.1%, 0.2%, and 0.7% products may have different reference applications and historical patent estates.[1]

When did olopatadine lose exclusivity?

The commercially important loss of exclusivity occurred in stages rather than on one date.

• The original branded 0.1% product lost practical market exclusivity after expiration of the relevant compound, formulation, and regulatory protections.
• Generic olopatadine 0.1% ophthalmic solutions subsequently entered the U.S. market through ANDA approvals.
• The 0.2% and 0.7% products retained differentiated strength and dosing positions after the 0.1% generic market developed.
• OTC conversion of certain branded olopatadine products expanded consumer access but did not restore broad patent exclusivity for the active ingredient.

The critical distinction is between active-ingredient freedom to operate and product-specific formulation protection. A company can generally compete in 0.1% olopatadine solution without challenging a live patent covering a higher-strength branded formulation, but a once-daily, preservative-free, or advanced-delivery product requires a separate patent and regulatory review.

What is the Orange Book status of Leader Olopatadine?

Leader Olopatadine is a generic product rather than an innovator reference product. The Orange Book generally identifies the reference listed drug, patents and exclusivities associated with that reference, and approved generic applicants. It does not provide a standalone commercial valuation of the Leader private-label brand.

For a standard olopatadine 0.1% ophthalmic solution:

1. The relevant reference product is the branded olopatadine ophthalmic solution.
2. Generic applicants may rely on the reference application through the ANDA pathway.
3. Approved generic products are subject to applicable labeling, quality, manufacturing, and bioequivalence requirements.
4. The product is not a biologic and does not create a biosimilar interchangeability issue.
5. Any live patent issue would ordinarily arise from a reference-product patent listing, a formulation patent, a device patent, or a method-of-use patent.

The commercial exposure from Orange Book litigation is therefore lower than for a still-protected branded ophthalmic product. The more important risks are price erosion, supply interruptions, preservative-related switching, and retailer bargaining power.

Which companies are challenging branded olopatadine products?

Generic ophthalmic manufacturers and private-label suppliers have challenged the branded market through approved olopatadine solutions. The relevant competitive group includes:

• Major Pharmaceuticals and other private-label suppliers
• Perrigo and other over-the-counter and generic ophthalmic manufacturers
• Akorn-related generic ophthalmic businesses
• Bausch + Lomb
• Sandoz and other broad generic suppliers
• Retailer-owned or retailer-exclusive pharmaceutical distributors

The exact supplier behind a Leader-labeled product may vary by product configuration, manufacturing contract, and distribution period. A private-label labeler does not necessarily own the manufacturing site or formulation technology.

What patent litigation affects Leader Olopatadine?

No major, product-specific patent litigation is broadly associated with the standard Leader olopatadine 0.1% solution as a standalone private-label product. Historical disputes have been more relevant to branded olopatadine products and to generic entry against particular reference products.

The principal legal risks are:

Risk	Assessment
Paragraph IV challenge to 0.1% reference product	Low practical significance where the relevant patents have expired
Litigation over 0.2% or 0.7% formulations	More relevant to higher-strength or once-daily products
Device patent dispute	Relevant if a company adopts a proprietary preservative-free multidose bottle
Method-of-use litigation	Limited for standard allergic-conjunctivitis labeling
Trade-secret or manufacturing dispute	Possible if a supplier changes formulation or technology
False patent certification or label carve-out issue	Product-specific and dependent on live Orange Book listings

A Paragraph IV filing would have created litigation risk if an applicant sought approval before expiry of an Orange Book-listed patent. That risk is materially lower for a conventional 0.1% solution now that generic products are established.

What excipient changes could create commercial opportunities?

Preservative-free unit-dose solution

A unit-dose preservative-free product would target patients with dry eye, chronic allergy, contact-lens intolerance, or frequent ophthalmic use. The principal disadvantages are higher packaging costs, greater logistics volume, and less convenient retail handling.

Commercial advantages include:

• Premium pricing relative to preserved generics
• Better positioning for ocular-surface-sensitive patients
• Reduced concern about chronic BAK exposure
• Potential use in ophthalmology practices and specialty pharmacies
• Greater differentiation from conventional retail generics

The main barrier is packaging economics. Unit-dose containers increase material usage, filling complexity, carton volume, and waste.

Preservative-free multidose bottle

Preservative-free multidose delivery has greater commercial value than a unit-dose format because it combines improved tolerability with consumer convenience. The delivery system must prevent microbial ingress without relying on BAK. Options include one-way valves, filtered air systems, non-return mechanisms, and container designs that limit contamination.

This strategy may require device development, human-factors testing, container-closure validation, extractables and leachables testing, and a regulatory pathway beyond a simple formulation-equivalent ANDA.

Reduced-BAK formulation

A reduced-preservative product could occupy an intermediate price position. It would have lower packaging and regulatory complexity than a fully preservative-free product but weaker differentiation. The commercial value depends on whether the lower BAK concentration can maintain antimicrobial performance throughout the labeled in-use period.

Ocular-surface comfort formulation

Potential excipient additions include lubricating or viscosity-modifying agents such as hypromellose, hydroxypropyl guar, polyethylene glycol, or hyaluronic acid. These ingredients may improve comfort and residence time, but they can also affect:

• Drop viscosity and blinking sensation
• Blurring after administration
• Sterilization and filtration
• Preservative efficacy
• Container compatibility
• Delivered dose
• Bioequivalence or comparative clinical performance

A comfort-enhanced product should not be treated as a simple generic substitution if the excipient system materially changes product performance.

Higher-strength or once-daily formulation

A 0.2% or 0.7% strategy could compete on dosing frequency rather than price. Once-daily use may improve adherence and support premium positioning. The regulatory and patent analysis is more complex because the product may correspond to a different reference listed drug, different clinical labeling, and potentially different formulation or device protection.

How does Leader compare with branded olopatadine products?

Attribute	Leader olopatadine 0.1%	Branded 0.2% or 0.7% products	Preservative-free opportunity
Dose frequency	Generally twice daily	Often once daily	Depends on strength and formulation
Preservative profile	Conventional BAK-preserved solution	Product-specific	Designed to avoid or reduce BAK
Price position	Low-cost generic	Premium or branded	Premium generic or specialty
Patent exposure	Low for standard 0.1% solution	Higher for specific branded strengths and devices	New formulation and device risk
Consumer differentiation	Limited	Brand, strength, dosing convenience	Tolerability, comfort, packaging
Manufacturing complexity	Low to moderate	Moderate	Moderate to high
Retail potential	High through private label	Established branded shelf presence	Targeted premium opportunity

Leader is strongest where retailers prioritize low acquisition cost and reliable supply. It is weaker where patients or prescribers prioritize preservative avoidance, once-daily dosing, or dry-eye compatibility.

What FDA regulatory pathway applies to new olopatadine excipient products?

A formulation that is qualitatively and quantitatively equivalent to the approved reference product may be suitable for an ANDA, subject to FDA requirements for pharmaceutical equivalence, product quality, sterility, and bioequivalence.

A materially different formulation may require a 505(b)(2) application. Relevant changes include:

• New preservative system
• Preservative-free multidose packaging
• New viscosity or residence-time technology
• Different strength
• New dosing frequency
• New indication or labeling claim
• Device-dependent delivery performance

For ophthalmic products, FDA review places particular weight on sterility assurance, particulate control, container-closure integrity, preservative effectiveness, stability, pH, osmolality, viscosity, and delivered volume. FDA guidance also addresses comparative performance and quality expectations for ophthalmic dosage forms.[2]

What manufacturing and intellectual-property barriers exist?

The standard preserved solution has relatively low manufacturing barriers. A capable sterile ophthalmic manufacturer can produce it using conventional compounding, sterilizing filtration, aseptic filling, and multidose packaging.

Higher barriers arise in:

• Preservative-free multidose systems
• Low-extractables plastic containers
• Valve and filter technology
• Long in-use stability
• Automated filling of small-volume unit doses
• Advanced viscosity or bioadhesive systems
• Container-closure systems with proprietary geometry

These technologies can support composition-of-matter, formulation, process, device, or packaging patents. A company pursuing differentiation should protect both the formulation and the delivery system because excipient-only patents are often narrower and easier to design around than device claims.

What licensing deals are relevant to olopatadine ophthalmic products?

Licensing is generally less important for the standard 0.1% generic solution because the active ingredient is commercially available and the core formulation is mature. Licensing becomes more relevant for:

• Proprietary preservative-free multidose bottles
• Drug-device combination systems
• Ocular-surface lubricating platforms
• Novel solubilization or viscosity technologies
• Retail private-label supply agreements
• Co-development with ophthalmic specialty manufacturers

For Leader, the most commercially realistic arrangement is contract manufacturing or private-label supply rather than a traditional active-ingredient license. A premium formulation could justify an exclusive retailer agreement or regional licensing structure.

How strong is the patent estate for Leader Olopatadine?

The patent estate for the conventional Leader product is weak as a blocking asset but potentially useful as a platform for new delivery technology.

Patent category	Strength for current Leader product
Active ingredient	Low
Conventional excipient combination	Low to moderate
BAK-preserved aqueous solution	Low
Preservative-free composition	Potentially moderate
Multidose preservative-free device	Potentially strong
Viscosity-enhanced ocular formulation	Moderate if supported by performance data
Manufacturing process	Moderate if process-specific and difficult to replicate
Brand or private-label channel	Commercial rather than patent protection

A defensible new product should combine formulation claims with device, manufacturing, and use claims. A single broad claim to olopatadine plus a common lubricant would likely face substantial validity and design-around pressure.

What generic launch scenarios exist?

Low-cost retail expansion

The company maintains the current formulation and competes through retailer distribution, supply reliability, and low acquisition cost. This is the lowest-risk strategy but has limited margin expansion potential.

Premium preservative-free launch

The company introduces a preservative-free product in unit-dose or multidose packaging. This creates a stronger price proposition and targets chronic-use and dry-eye patients.

Once-daily strength strategy

The company develops a higher-strength product with once-daily labeling. This can improve adherence and create a differentiated retail product, but it carries greater development, regulatory, and patent risk.

Portfolio strategy

A supplier offers:

• Preserved 0.1% solution for price-sensitive consumers
• Preservative-free 0.1% solution for ocular-surface-sensitive users
• Higher-strength once-daily product for convenience-focused consumers

This portfolio approach reduces dependence on one price segment and allows retailers to place products across multiple shelf positions.

What revenue exposure does the product create?

Leader-specific revenue is not generally disclosed separately from broader private-label pharmaceutical sales. The product’s revenue exposure is therefore best assessed through market structure rather than public brand-level sales.

The main revenue drivers are:

1. Seasonal allergy demand.
2. Retailer distribution breadth.
3. Unit price and reimbursement status.
4. Availability of competing generic suppliers.
5. Market share migration from branded products.
6. Preservative-free premium adoption.
7. Supply continuity during allergy seasons.

The standard 0.1% solution is likely to face price pressure because multiple generic and private-label alternatives exist. Margin expansion is more plausible through differentiated packaging, preservative-free delivery, or exclusive retail distribution than through the conventional formulation alone.

Key Takeaways

• Leader Olopatadine Hydrochloride Ophthalmic Solution is a conventional 0.1% generic ophthalmic solution.
• Its excipient system uses BAK, phosphate buffer, sodium chloride, edetate disodium, pH adjusters, and purified water.
• The standard formulation has low patent-based barriers and high generic price competition.
• Biosimilar risk does not apply because olopatadine is a small molecule.
• The principal commercial weakness is limited differentiation from other preserved olopatadine products.
• Preservative-free unit-dose and multidose systems offer the clearest formulation opportunities.
• A new preservative-free multidose product may require device development and a 505(b)(2) strategy rather than a simple ANDA.
• Higher-strength and once-daily formulations offer convenience-based differentiation but create greater regulatory and patent exposure.
• Private-label supply, retailer exclusivity, and reliable seasonal availability are more commercially important than licensing the mature active ingredient.
• The strongest new patent position would combine formulation, device, manufacturing, and method-of-use claims.

FAQs

Is Leader Olopatadine 0.1% the same as Patanol?

It is generally intended to be therapeutically equivalent to the reference olopatadine 0.1% ophthalmic solution when approved through the applicable generic pathway. Inactive ingredients, packaging, labeling, and supplier may differ.

Does Leader Olopatadine contain benzalkonium chloride?

Yes. The labeled formulation uses benzalkonium chloride as a preservative. Patients with chronic ocular-surface sensitivity may prefer a preservative-free alternative.

Can a company patent a new olopatadine eye-drop formulation?

Yes. Patentable subject matter may include a novel excipient combination, preservative-free system, multidose container, manufacturing process, viscosity profile, stability improvement, or dosing method. Patent strength depends on novelty, non-obviousness, claim scope, and supporting data.

Is olopatadine subject to biosimilar competition?

No. Olopatadine is a small-molecule drug. Competition occurs through generic drug applications, not biosimilar applications.

What is the best commercial opportunity beyond the current Leader formulation?

A preservative-free multidose product offers the strongest combination of consumer differentiation, premium pricing potential, and recurring use value. Its development burden is materially higher than that of a conventional preserved generic.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

2. U.S. Food and Drug Administration. (2008). Guidance for industry: Ophthalmic drug products, quality considerations. U.S. Department of Health and Human Services.

3. U.S. National Library of Medicine. (2024). DailyMed: Olopatadine hydrochloride ophthalmic solution 0.1% labeling. National Institutes of Health.

4. U.S. Food and Drug Administration. (2020). FDA approves first over-the-counter eye drop to treat ocular itching associated with allergies. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2023). Approved drug products database and electronic Orange Book resources. U.S. Department of Health and Human Services.